- Allarity Granted Hearing Before Nasdaq Panel to Present Plan of Regaining Compliance
- Allarity Therapeutics’ Dual PARP/Tankyrase Inhibitor, Stenoparib, Continues to Show Extended Clinical Benefit in Advanced Ovarian Cancer
- Allarity Therapeutics Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement
- Allarity Therapeutics Reports First Quarter Financial Results and Highlights, including Clear Clinical Benefits from Phase 2 Trial, NASDAQ Compliance, and Significant Improvement in Cash and Equity Balances
- Allarity Therapeutics Announces that All Series A Preferred and All Variable Priced Warrants have Converted to Common Stock
- Allarity Therapeutics Exceeds Nasdaq’s Minimum Equity Requirement; Requests Voluntarily Withdrawal of Form S-1
- Allarity Therapeutics’ Stenoparib Shows Clear Clinical Benefit and Achieves Significant Milestone with Early Conclusion of Phase 2 Trial in Advanced Ovarian Cancer
- Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Requirement
- Allarity Therapeutics Receives NASDAQ-Approved Extension to Regain Compliance with Nasdaq Listing Rule 5550(b)(1)
- Allarity Therapeutics Announces 1-for-20 Reverse Stock Split
More ▼
Key statistics
As of last trade Allarity Therapeutics Inc (ALLR:NAQ) traded at 0.2027, 9.57% above its 52-week low of 0.185, set on Jun 26, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.1984 |
---|---|
High | 0.2069 |
Low | 0.1953 |
Bid | 0.2027 |
Offer | 0.2064 |
Previous close | 0.198 |
Average volume | 9.02m |
---|---|
Shares outstanding | 25.59m |
Free float | 25.59m |
P/E (TTM) | -- |
Market cap | 5.07m USD |
EPS (TTM) | -599.34 USD |
Data delayed at least 15 minutes, as of Jul 05 2024 16:12 BST.
More ▼